Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. This phase II trial is studying how well lapatinib works in treating patients with
persistent or recurrent ovarian epithelial or peritoneal cancer.